1,4-Benzodioxane-6-carboxylic acidCAS# 4442-54-0 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 4442-54-0 | SDF | Download SDF |
| PubChem ID | 2758833 | Appearance | Powder |
| Formula | C9H8O4 | M.Wt | 180 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 2,3-dihydro-1,4-benzodioxine-6-carboxylic acid | ||
| SMILES | C1COC2=C(O1)C=CC(=C2)C(=O)O | ||
| Standard InChIKey | JWZQJTGQFHIRFQ-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C9H8O4/c10-9(11)6-1-2-7-8(5-6)13-4-3-12-7/h1-2,5H,3-4H2,(H,10,11) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
1,4-Benzodioxane-6-carboxylic acid Dilution Calculator
1,4-Benzodioxane-6-carboxylic acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 5.5556 mL | 27.7778 mL | 55.5556 mL | 111.1111 mL | 138.8889 mL |
| 5 mM | 1.1111 mL | 5.5556 mL | 11.1111 mL | 22.2222 mL | 27.7778 mL |
| 10 mM | 0.5556 mL | 2.7778 mL | 5.5556 mL | 11.1111 mL | 13.8889 mL |
| 50 mM | 0.1111 mL | 0.5556 mL | 1.1111 mL | 2.2222 mL | 2.7778 mL |
| 100 mM | 0.0556 mL | 0.2778 mL | 0.5556 mL | 1.1111 mL | 1.3889 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Vandetanib (ZD6474)
Catalog No.:BCC3883
CAS No.:443913-73-3
- Glycosmisic acid
Catalog No.:BCN3650
CAS No.:443908-19-8
- Norkhellol
Catalog No.:BCN5497
CAS No.:4439-68-3
- 3-Chloro-4-(3-fluorobenzyloxy)nitrobenzene
Catalog No.:BCC8626
CAS No.:443882-99-3
- JNJ-7706621
Catalog No.:BCC2171
CAS No.:443797-96-4
- BC 11 hydrobromide
Catalog No.:BCC2381
CAS No.:443776-49-6
- Z-DL-Met-OH
Catalog No.:BCC2759
CAS No.:4434-61-1
- SF 11
Catalog No.:BCC7805
CAS No.:443292-81-7
- Isopedicin
Catalog No.:BCN4633
CAS No.:4431-42-9
- Ligustilide
Catalog No.:BCN1031
CAS No.:4431-01-0
- Metronidazole
Catalog No.:BCC9046
CAS No.:443-48-1
- Tabersonine
Catalog No.:BCN5496
CAS No.:4429-63-4
- 2-Cyclohexylethylamine
Catalog No.:BCN1794
CAS No.:4442-85-7
- Norwogonin
Catalog No.:BCN3190
CAS No.:4443-09-8
- Pazopanib (GW-786034)
Catalog No.:BCC1286
CAS No.:444731-52-6
- CMX001
Catalog No.:BCC4106
CAS No.:444805-28-1
- Cyclopamine
Catalog No.:BCN2964
CAS No.:4449-51-8
- Warangalone
Catalog No.:BCN4788
CAS No.:4449-55-2
- AM1241
Catalog No.:BCC2551
CAS No.:444912-48-5
- TC-O 9311
Catalog No.:BCC7900
CAS No.:444932-31-4
- EBPC
Catalog No.:BCC6677
CAS No.:4450-98-0
- 1,4:3,6-Dianhydro-α-D-glucopyranose
Catalog No.:BCC8420
CAS No.:4451-30-3
- ZM 449829
Catalog No.:BCC2444
CAS No.:4452-06-6
- BMS-345541(free base)
Catalog No.:BCC5374
CAS No.:445430-58-0
Study of the anticancer properties of tin(IV) carboxylate complexes on a panel of human tumor cell lines.[Pubmed:22170592]
ChemMedChem. 2012 Feb 6;7(2):301-10.
A group of organotin(IV) complexes were prepared: [SnCy3 (DMNI)] (1), [SnCy3 (BZDO)] (2), [SnCy3 (DMFU)] (3), and [SnPh2 (BZDO)2 ] (4), for which DMNIH=2,6-dimethoxynicotinic acid, BZDOH=1,4-Benzodioxane-6-carboxylic acid, and DMFUH=2,5-dimethyl-3-furoic acid. The cytotoxic activities of compounds 1-4 were tested against pancreatic carcinoma (PANC-1), erythroleukemia (K562), and two glioblastoma multiform (U87 and LN-229) human cell lines; they show very high antiproliferative activity, with IC50 values in the 150-700 nM range after incubation for 72 h. Distribution of cellular DNA upon treatment with 1-4 revealed that whereas compounds 1-3 induce apoptosis in most of the cell lines, compound 4 does not affect cell viability in any cell line tested, indicating a possible difference in cytotoxic mechanism. Studies with the daunomycin-resistant K562/R cell line expressing P-glycoprotein (Pgp) showed that compounds 1-4 are not substrates of this protein efflux pump, indicating that these compounds do not induce acquisition of multidrug resistance, which is associated with the overexpression of Pgp.
Anticancer activity of dinuclear gallium(III) carboxylate complexes.[Pubmed:19926362]
Eur J Med Chem. 2010 Feb;45(2):519-25.
The reaction of 3-methoxyphenylacetic acid, 4-methoxyphenylacetic acid, mesitylthioacetic acid, 2,5-dimethyl-3-furoic acid and 1,4-Benzodioxane-6-carboxylic acid with trimethylgallium (1:1) yielded the dimeric complexes [Me(2)Ga(micro-O(2)CCH(2)C(6)H(4)-3-OMe)](2) (1), [Me(2)Ga(micro-O(2)CCH(2)C(6)H(4)-4-OMe)](2) (2), [Me(2)Ga(micro-O(2)CCH(2)SMes)](2) (3) (Mes=2,4,6-Me(3)C(6)H(2)), [Me(2)Ga{micro-O(2)C(Fur)}](2) (4) (Fur=2,5-dimethylfuran) and [Me(2)Ga{micro-O(2)C(Bdo)}](2) (5) (Bdo=1,4-benzodioxane) respectively. The molecular structure of 5 was determined by X-ray diffraction studies. The cytotoxic activity of the gallium(III) complexes (1-5) was tested against human tumor cell lines 8505C anaplastic thyroid cancer, A253 head and neck tumor, A549 lung carcinoma, A2780 ovarian cancer, DLD-1 colon carcinoma and compared with that of cisplatin. Taking into account the standard deviation, there is no significant difference in the activity for any of the compounds in any cell line. However, complex 5 presents the best IC(50) value against A253 head and neck tumor (6.6+/-0.2 microM), while complex 3 seems to be the most active against A2780 ovarian cancer (12.0+/-0.4 microM) and marginally on DLD-1 colon carcinoma (12.4+/-0.1 microM).
Study of the cytotoxic activity of di and triphenyltin(IV) carboxylate complexes.[Pubmed:18760840]
J Inorg Biochem. 2008 Dec;102(12):2087-96.
The reaction of 3-methoxyphenylacetic acid (3-MPAH), 4-methoxyphenylacetic acid (4-MPAH), 2,5-dimethyl-3-furoic acid (DMFUH) or 1,4-Benzodioxane-6-carboxylic acid (BZDOH) with triphenyltin(IV) chloride (1:1) or diphenyltin(IV) dichloride (2:1) in the presence of triethylamine yielded the compounds [SnPh3(3-MPA)] (1), [SnPh3(4-MPA)] (2), [SnPh3(DMFU)] (3), [SnPh3(BZDO)] (4), [SnPh2(3-MPA)2] (5), [SnPh2(4-MPA)2] (6), [SnPh2(DMFU)2] (7) and [SnPh2(BZDO)2] (8), respectively. The tetranuclear complex [{Me2(DMFU)SnOSn(DMFU)Me2}2] (9) was prepared by the reaction of dimethyltin(IV) oxide and 2,5-dimethyl-3-furoic acid (DMFUH). The molecular structures of 3, 4 and 9, were determined by X-ray diffraction studies. The cytotoxic activity of the carboxylic acids (3-MPAH, 4-MPAH, BZDOH and DMFUH) and di (5-8) and triphenyltin(IV) complexes (2-4) was tested against tumor cell lines human adenocarcinoma HeLa, human myelogenous leukemia K562, human malignant melanoma Fem-x and normal immunocompetent cells, peripheral blood mononuclear cells PBMC. Triphenyltin(IV) complexes show higher activities than the diphenyltin(IV) derivatives. The most active compound is [SnPh3(DMFU)] (3) with IC50 value of 0.15+/-0.01, 0.051+/-0.004, 0.074+/-0.004, 0.20+/-0.01, 0.15+/-0.02 on HeLa, K562, Fem-x, rested and stimulated PBMC, respectively, while the most selective are [SnPh2(3-MPA)2] (5), [SnPh(2)(DMFU)2] (7) and [SnPh((BZDO)2] (8). Compounds 3, 5, 7 and 8 present higher activities than cisplatin in all the tested cells and relative high selectivity especially on K562 cells.
